Of Standards for Extra-Judicial Behavior

A Review of The Brandeis/Frankfurter Connection: The Secret Political Activities of Two Supreme Court Justices by Bruce Allen Murph

Administration of Justice Is Archaic -The Rise of Modern Court Administration: Assessing Roscoe Pound\u27s Court Administration Prescriptions

Note. This is a heavily edited and partially reorganized version of the CC/COSCA panel on The Rise of Modem Court Administration. In it, Sue Dosal and Mary McQueen assess three changes advocated by Pound in respect to the organization of courts, based on their experiences as state court administrators in Minnesota and Washington, and their familiarity with court administration in other states. Russell Wheeler introduced the session, posed the questions, and was primarily responsible for editing, annotating, and partially reorganizing the panel transcript, which Dosal and McQueen edited as well. Conference of Chief Justices and Conference of State Court Administrators Annual Meeting July 29-August 2, 2006 Indianapolis, Indiana

Pharmacotherapy for treatment-resistant schizophrenia

Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine